Of the seven patients with myasthenia gravis, baseline neurologic exam, comorbidities (diabetes, age, BMI) and medication regimen prior to infection with SARS-CoV-2 did not clearly appear to affect the probability of requiring admission or mortality. Five of the seven patients required hospitalization, with two eventually expiring. Both patients who expired had the longest disease duration of the group (mean = 9 years), with respiratory failure as the cause of clinical decompensation. Higher inflammatory markers (i.e. ESR, CRP, D-dimer) were found on serologic studies of those two patients, with marked increases in ferritin and D-dimer levels. Lower absolute lymphocyte count appears to be associated with worse clinical outcome.  Of note, two of the five hospitalized patients received a dose of a monoclonal antibody against interleukin-6 (i.e. tocilizumab) and had marked improvement in their clinical course, ultimately discharged at their baseline neurologic status.